biotech development and production of affordable medication worldwide
I began this London-based Biotech startup with the vision of a world in which medication and treatments would be gene-specific and tailored to the genetic outlook of patients.
An & An Global believes in collective global efforts for solving global healthcare problems. We believe that our diversity makes us stronger hence, we are keen to hear from institutions, scientists, and collaborators with interests aligned to ours for mutually-beneficial cooperation.
An & An is helping in the fight against COVID-19 by aiding in the development and distribution of COVID-19 lateral flow test kits in UK, Africa and India. We ensure that our clients are provided with highly sensitive, specific and state of the art lateral flow test kits. We are authorised distributors for Sona Nanotech.
An & An Biotech is responding to COVID-19 by working on an app which indicates the number of shoppers in-store at any given point in time and help customers to avoid overcrowding. As a bonus, this app will also tell customers the location of in-store items and their stock levels to avoid unnecessary movements around the shops and also save time spent shopping.
This new venture is proceeding rapidly hence we are keen to hear from companies and collaborators who would like form part of our trial zones.
As part of our efforts to facilitate knowledge transfer and advanced research, we provide research consultation for researchers across the globe in a broad array of subjects. If you're a researcher with pressing issues requiring a solution, don't hesitate to contact us using the contact form at the bottom of this page or by pressing the (yellow and black) chat box and we will be in touch immediately.
One of the key focal areas of An & An Global is developing pharmacogenomic modules which will enable Doctors to prescribe medication to patients based on their genetic outlook, hence minimising side-effects as much as possible.
Our current focus is on beta-blocker anti-hypertensives and anti-cholesterol statins. A research conducted in the UK on 165,000 patients and reported on the BBC highlighted limited effectiveness of statins in 50% of subjects treated. With gene-specific prescriptions of statins, this percentage could be increased significantly.
We have a strong belief that high quality medication should be affordable especially for low income families in developing countries. This can be made possible via cutting-edge technology and know-how. An & An Global is passionate about using our technical and financial resources to help in the production and supply of affordable medicines and natural wellness products globally.
Our current focus is on Africa, Asia and Middle East. You can read more about one of such projects in the projects section. We welcome collaborators and investors who share this dream and passion with interest in beginning a similar venture with us.
An & An Global has a primary aim to develop tomorrow's biotechnology today. We employ cutting-edge technology and biomedical research to resolve existing and upcoming challenges in healthcare, disease diagnosis, medication and treatment development.
Our passion is to promote the production of affordable medication and wellness products using state of the art technology, experience and know-how.
We provide research consultation and promote the training and development of tomorrow's Biomedical Research Scientists today by organising and facilitating workshops for researchers globally.
Sign up to hear from us.
An & An Global Limited is a company limited by shares registered in England & Wales No. 12774627 and VAT No. 381010539 . Registered Office: 85 Great Portland Street, London W1W 7LT
Copyright © 2021 AN & AN GLOBAL LIMITED - All Rights Reserved.
Powered by GoDaddy Website Builder